Studying brain imaging to understand drug-resistant epilepsy
Uses brain scans to study seizure-causing areas in adults with drug-resistant epilepsy.
Plain-language title generated from the registry record
Registry title: Exploring the Characteristics of Epileptogenic Foci in Drug-Resistant Epilepsy Based on Multimodal Imaging Technology
Key facts
- Where
- Xi'an, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06557720, who can take part
Where in China
- Xijing Hospital of Air Force Military Medical UniversityXi'an, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xijing Hospital
- Trial code
- NCT06557720
- Record updated
- 25 June 2025
- Original description
Using multimodal imaging technology, this study aims to explore the characteristics of epileptogenic foci in patients with drug-resistant epilepsy and identify key network nodes (such as central nodes) to provide more assistance for the diagnosis of drug-resistant epilepsy.Read full original descriptionShow less
Exploring the Characteristics of Epileptogenic Foci in Drug-Resistant Epilepsy Using Multimodal Imaging Techniques: A Prospective Observational Cohort Study
Using multimodal imaging technology, this study aims to explore the characteristics of epileptogenic foci in patients with drug-resistant epilepsy and identify key network nodes (such as central nodes) to provide more assistance for the diagnosis of drug-resistant epilepsy.
Inclusion: Aged ≥18 years old; Meet the 2010 International League Against Epilepsy (ILAE) diagnostic criteria for drug-resistant epilepsy; Duration of epilepsy ≥2 years, with an average seizure frequency of ≥2 times per month in the 3 months prior to enrollment; Adequate intake of two or more anti-epileptic drugs, with no intervention in the treatment plan during the trial period; Capable of cooperating to complete treatment and related examination items; The patient and family fully understand and voluntarily sign the informed consent form.
Exclusion: In a state of continuous epileptic seizures; Complicated with severe infections, cerebrovascular diseases, malignant tumors, and other diseases, accompanied by severe dysfunction of the heart, liver, kidney, or other organs, or with mental disorders, or with uncorrectable hyperglycemia, or 3.patients on long-term use of corticosteroid medications; 4.Pregnant or lactating women; 5.Contraindications for PET, MR, EEG examinations; 6.Patients with examinations (with ferromagnetic metal implants in the body; high fever); 7.Participating in other clinical trials at the same time; 8.The patient or family withdraws the informed consent form.